By Mill Chart
Last update: Apr 30, 2024
Our stock screening tool has pinpointed BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) as a growth stock that isn't overvalued. NASDAQ:BMRN is excelling in various growth indicators while maintaining a solid financial footing. Furthermore, it remains attractively priced. Let's delve into the specifics below.
ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:BMRN, the assigned 7 reflects its growth potential:
To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:BMRN has achieved a 6 out of 10:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:BMRN, the assigned 5 for health provides valuable insights:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:BMRN was assigned a score of 7 for profitability:
Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.
For an up to date full fundamental analysis you can check the fundamental report of BMRN
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
BIOMARIN PHARMACEUTICAL INC
NASDAQ:BMRN (5/8/2024, 7:00:01 PM)
After market: 81.83 0 (0%)81.83
-0.75 (-0.91%)
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We live in the best of times where life is not capped at 45 or 50 years of age,...
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in...
Reviewing analyst downgrades may help safeguard investment portfolios amid market uncertainty and Citi price target cuts.
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023.
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.
BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biomarin Pharmaceutical (NASDAQ:BMRN) just reported results for the first quart...
First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and...
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host...